211 related articles for article (PubMed ID: 17350328)
1. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy.
Saussez S; Lorfevre F; Lequeux T; Laurent G; Chantrain G; Vertongen F; Toubeau G; Decaestecker C; Kiss R
Oral Oncol; 2008 Jan; 44(1):86-93. PubMed ID: 17350328
[TBL] [Abstract][Full Text] [Related]
2. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas.
Saussez S; Camby I; Toubeau G; Kiss R
Head Neck; 2007 Sep; 29(9):874-84. PubMed ID: 17315170
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 upregulation during tumor progression in head and neck cancer.
Saussez S; Decaestecker C; Mahillon V; Cludts S; Capouillez A; Chevalier D; Vet HK; André S; Toubeau G; Leroy X; Gabius HJ
Laryngoscope; 2008 Sep; 118(9):1583-90. PubMed ID: 18677282
[TBL] [Abstract][Full Text] [Related]
5. Expression of galectins in head and neck squamous cell carcinoma.
Gillenwater A; Xu XC; el-Naggar AK; Clayman GL; Lotan R
Head Neck; 1996; 18(5):422-32. PubMed ID: 8864733
[TBL] [Abstract][Full Text] [Related]
6. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH
J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374
[TBL] [Abstract][Full Text] [Related]
7. Galectin-1: a link between tumor hypoxia and tumor immune privilege.
Le QT; Shi G; Cao H; Nelson DW; Wang Y; Chen EY; Zhao S; Kong C; Richardson D; O'Byrne KJ; Giaccia AJ; Koong AC
J Clin Oncol; 2005 Dec; 23(35):8932-41. PubMed ID: 16219933
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of circulating galectins as colorectal cancer markers.
Watanabe M; Takemasa I; Kaneko N; Yokoyama Y; Matsuo E; Iwasa S; Mori M; Matsuura N; Monden M; Nishimura O
Oncol Rep; 2011 May; 25(5):1217-26. PubMed ID: 21369702
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Svetic B; Vrhovec I; Skrk J
Neoplasma; 2001; 48(1):66-71. PubMed ID: 11327540
[TBL] [Abstract][Full Text] [Related]
10. Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma.
Homer JJ; Greenman J; Drevs J; Marme D; Stafford ND
Head Neck; 2002 Aug; 24(8):773-8. PubMed ID: 12203803
[TBL] [Abstract][Full Text] [Related]
11. Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer.
Saussez S; Cucu DR; Decaestecker C; Chevalier D; Kaltner H; André S; Wacreniez A; Toubeau G; Camby I; Gabius HJ; Kiss R
Ann Surg Oncol; 2006 Jul; 13(7):999-1009. PubMed ID: 16788763
[TBL] [Abstract][Full Text] [Related]
12. Expression of IL-18 in patients with head and neck squamous cell carcinoma.
Riedel F; Adam S; Feick P; Haas S; Götte K; Hörmann K;
Int J Mol Med; 2004 Feb; 13(2):267-72. PubMed ID: 14719133
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD44 is a potential marker for the early detection of head and neck cancer.
Franzmann EJ; Reategui EP; Pedroso F; Pernas FG; Karakullukcu BM; Carraway KL; Hamilton K; Singal R; Goodwin WJ
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1348-55. PubMed ID: 17627000
[TBL] [Abstract][Full Text] [Related]
14. High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas.
Saussez S; Decaestecker C; Lorfevre F; Cucu DR; Mortuaire G; Chevalier D; Wacreniez A; Kaltner H; André S; Toubeau G; Camby I; Gabius HJ; Kiss R
Int J Oncol; 2007 May; 30(5):1109-17. PubMed ID: 17390012
[TBL] [Abstract][Full Text] [Related]
15. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
16. Concentrations of galectin-3 in the sera of normal controls and cancer patients.
Iurisci I; Tinari N; Natoli C; Angelucci D; Cianchetti E; Iacobelli S
Clin Cancer Res; 2000 Apr; 6(4):1389-93. PubMed ID: 10778968
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
18. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.
Koopmann J; Thuluvath PJ; Zahurak ML; Kristiansen TZ; Pandey A; Schulick R; Argani P; Hidalgo M; Iacobelli S; Goggins M; Maitra A
Cancer; 2004 Oct; 101(7):1609-15. PubMed ID: 15378479
[TBL] [Abstract][Full Text] [Related]
19. Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy.
Snitcovsky I; Leitão GM; Pasini FS; Brunialti KC; Mangone FR; Maistro S; de Castro G; Villar RC; Federico MH
Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):807-11. PubMed ID: 19687403
[TBL] [Abstract][Full Text] [Related]
20. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas.
Kim SJ; Lee SJ; Sung HJ; Choi IK; Choi CW; Kim BS; Kim JS; Yu W; Hwang HS; Kim IS
Acta Haematol; 2008; 120(4):211-6. PubMed ID: 19153476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
